Proteome Sciences PLC Loan Amendment (8662T)
30 Marzo 2021 - 12:00AM
UK Regulatory
TIDMPRM
RNS Number : 8662T
Proteome Sciences PLC
30 March 2021
30 March 2021
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Loan amendment
On 3 July 2018, the Company entered into a GBP1 million loan
facility with Vulpes Investment Management Private Limited ("VIM")
(the "Loan"). The Directors of Proteome Sciences are now pleased to
announce that the Loan has been amended such that the Loan (of
which GBP700,000 is currently drawn) and all accrued interest is
now repayable on 1 May 2022 (previously 1 May 2021) (the "Loan
Amendment"). All other terms of the Loan remain the same as
announced on 3 July 2018, including that interest will accrue at
the annual rate of 2.5 per cent. above the UK sterling base rate of
Barclays Bank plc.
Mr Martin Diggle, Non-Executive Director of Proteome Sciences,
is a director and partner of VIM. VIM manages the Vulpes Life
Sciences Fund, which is the shareholder of 22.3 per cent. of
Proteome Sciences. By virtue of Mr Diggle being a director of the
Company and a partner and director of VIM, the Loan Amendment
constitutes a related party transaction in accordance with the AIM
Rules for Companies. Accordingly, the directors independent of the
transaction, being all directors of the Company save for Mr Diggle,
consider, having consulted with the Company's nominated adviser,
that the Loan Amendment is fair and reasonable insofar as the
Company's shareholders are concerned.
For further information please contact:
Proteome Sciences plc
Mariola Soehngen, M.D., Chief Executive Officer
Dr Ian Pike, Chief Scientific Officer Tel: +44 (0)20 7043 2116
Richard Dennis, Chief Commercial Officer
Allenby Capital Limited (AIM Nominated Adviser & Broker)
John Depasquale / Jeremy Porter Tel: +44 (0) 20 3328 5656
About Proteome Sciences plc. ( www.proteomics.com )
Proteome Sciences plc is a specialist provider of contract
proteomics services to enable drug discovery, development and
biomarker identification, and employs proprietary workflows for the
optimum analysis of tissues, cells and body fluids. SysQuant(R) and
TMT(R)MS2 are unbiased methods for identifying and contextualising
new targets and defining mechanisms of biological activity, while
analysis using Super-Depletion and TMTcalibrator(TM) provides
access to over 8,500 circulating plasma proteins for the discovery
of disease-related biomarkers. Targeted assay development using
mass spectrometry delivers high sensitivity, interference-free
biomarker analyses in situations where standard ELISA assays are
not available.
The Company has its headquarters in London, UK, with laboratory
facilities in Frankfurt, Germany.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUKUNRAWUOUAR
(END) Dow Jones Newswires
March 30, 2021 02:00 ET (06:00 GMT)
Proteome Sciences (LSE:PRM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Proteome Sciences (LSE:PRM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
